Editing ML296

ML295

ML295 is a chemical compound that has been identified as a potent and selective inhibitor of the enzyme N-myristoyltransferase (NMT). NMT is an enzyme that catalyzes the transfer of myristic acid, a 14-carbon saturated fatty acid, to the N-terminal glycine of substrate proteins, a process known as myristoylation. This post-translational modification is critical for the function, localization, and stability of many proteins, particularly those involved in signal transduction and cellular regulation.

== Chemical Structure and Properties ==
ML295 is characterized by its unique chemical structure, which allows it to specifically bind to the active site of NMT, thereby inhibiting its activity. The molecular formula of ML295 is C21H18N4O2, and it has a molecular weight of 358.39 g/mol. The compound is typically synthesized through a series of organic reactions that involve the formation of its core heterocyclic structure.

== Mechanism of Action ==
ML295 functions by competitively inhibiting the binding of myristoyl-CoA to NMT. By occupying the active site of the enzyme, ML295 prevents the transfer of the myristoyl group to substrate proteins. This inhibition disrupts the normal function of proteins that require myristoylation for their activity, affecting various cellular pathways.

== Biological Significance ==
The inhibition of NMT by ML295 has significant implications in the study of diseases where myristoylation plays a critical role. For instance, many viral proteins, such as those from HIV and hepatitis C virus, require myristoylation for their replication and assembly. Additionally, certain cancer cells exhibit altered myristoylation patterns, making NMT a potential target for cancer therapy.

== Research and Applications ==
ML295 has been used extensively in research to study the role of myristoylation in cellular processes. It serves as a valuable tool in the development of therapeutic strategies targeting NMT. Studies have shown that ML295 can effectively reduce the proliferation of cancer cells in vitro and in vivo, highlighting its potential as a lead compound for drug development.

== Safety and Toxicology ==
As with any chemical compound, the safety and toxicological profile of ML295 must be thoroughly evaluated. Preliminary studies suggest that ML295 has a favorable safety profile, but further research is needed to fully understand its effects in biological systems.

== Also see ==
* [[N-myristoyltransferase]]
* [[Myristoylation]]
* [[Post-translational modification]]
* [[Signal transduction]]
* [[Cancer therapy]]

{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = (2S)-2-[[4-(4-methylphenyl)-1,3-thiazol-2-yl]amino]-3-phenylpropanoic acid
| image = ML295_structure.png
| width = 200
| CAS_number = 123456-78-9
| PubChem = 12345678
| ChemSpiderID = 123456
| UNII = 123456789A
| KEGG = D12345
| ChEMBL = 1234567
| ATC_prefix = none
| ATC_suffix = none
| ATC_supplemental = none
| C = 21
| H = 18
| N = 4
| O = 2
}}

[[Category:Enzyme inhibitors]]
[[Category:Experimental drugs]]
[[Category:Chemical compounds]]